IL-16 qPCR Primer Pairs, Human 基本信息
Target Details
Product Details
Component:
1 vial of lyophilized qPCR primer mix (1 nmol each primer, sufficient for 200 numbers of 25 μl reactions).
QPCR Primer Description:
Verified forward and reverse primers for analyzing the quantitative expression of gene.
Application & Quality
应用:
SYBR® Green-based quantitative real-time PCR (qPCR).
质控:
The primer mix has been verified to generate satisfactory qPCR data on Roche Applied-science LightCycler® 480 Ⅱ.
储存 & 运输
运输:
Lyophilized qPCR primer mix is shipped at ambiente temperatura
储存:
The lyophilized product is stable for one year from date of receipt when stored at -20℃. The suspended product is stable for six months from date of receipt when stored at -20℃.
***Sino biological qEASY qPCR primer pairs are used for SYBR Green-based real-time RT-PCR, The primers are designed by using SBI's proprietary primer design algorithm. Our primer collection covers the entire human genomes. It can be widely applied in the quantitative analysis of gene expression.***
Features and Advantages
Unique Primer Design
To avoid genomic DNA amplification, at least one primer is designed crosses the junction of exons according to the conserved region of a specific gene with all variants.
Strict Validation Process
Confirmed in positive organizations; screened the primer with high specificity and high sensitivity.
Uniform PCR conditions, Saving time and cost
~100% amplification curve, ensuring the accuracy of the RNA quantitative
IL-16 qPCR Primer Pairs, Human Alternative Names
LCF qPCR Primer Pairs, Human;NIL16 qPCR Primer Pairs, Human;prIL-16 qPCR Primer Pairs, Human;PRIL16 qPCR Primer Pairs, Human
IL-16 Background Information
References
Maciaszek JW, et al. (1997) IL-16 represses HIV-1 promoter activity. J Immunol. 158(1): 5-8. Zhou P, et al. (1997) Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat Med. 3(6): 659-64. Theodore AC, et al. (1996) CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol. 157(5): 1958-64.